BAYER, ONYX SUBMIT APPLICATION FOR EU APPROVAL OF SORAFENIB CANCER TREATMENT

Bayer Pharmaceuticals Corp and Onyx Pharmaceuticals Inc announced that Bayer has submitted an application for EU approval of their sorafenib cancer treatment to the European Medicines Agency (EMEA) in London. Sorafenib is used to treat kidney cancer. It is being jointly developed by Bayer and Onyx. The companies also announced a Phase III trial of this drug in the EU for patients with advanced kidney cancer.

Forbes (http://www.forbes.com/markets/feeds/afx/2005/09/12/afx2217335.html)